AR021924A1 - BENZISOXAZOLES Y FENONAS COMO ALFA-2-ANTAGONISTAS , UN PROCESO PARA SU PREPARACIoN , COMPOSICIONES FARMACÉUTICAS Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO. - Google Patents

BENZISOXAZOLES Y FENONAS COMO ALFA-2-ANTAGONISTAS , UN PROCESO PARA SU PREPARACIoN , COMPOSICIONES FARMACÉUTICAS Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO.

Info

Publication number
AR021924A1
AR021924A1 ARP990106577A ARP990106577A AR021924A1 AR 021924 A1 AR021924 A1 AR 021924A1 AR P990106577 A ARP990106577 A AR P990106577A AR P990106577 A ARP990106577 A AR P990106577A AR 021924 A1 AR021924 A1 AR 021924A1
Authority
AR
Argentina
Prior art keywords
alkyl
preparation
benzisoxazoles
phenones
alfa
Prior art date
Application number
ARP990106577A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR021924A1 publication Critical patent/AR021924A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se relaciona con compuestos de formula (1) las formas N-oxido, las sales de adicion farmacéuticamente aceptables y las formasestereoquímicamente isoméricas de los mismos, en donde Alk es alcanodiilo C5-12; n es 1 o 2; p es 1 yq es 2; o p es 2 y q es 1; X es -O-, -S-,-S(=O)-,-S(=O)2- o NR2 cada R1 es independientemente hidrogeno, halogeno, alquilo C1-6, nitro, hidroxi o alquiloxi C1-4; R2 es hidrogeno, alquilo C1-6, arilo o alquiloC1-6 sustituido con arilo; arilo esfenilo o fenilo sustituido con un halogeno o alquilo C1-6; D es un 3-bencisoxazolilo o benzofenona opcionalmente sustituida; que tienen actividad antagonista de alfa2-receptores adrenérgicos centrales. Además se relaciona con su preparacion, con suuso far macéutico y concomposiciones.
ARP990106577A 1998-12-21 1999-12-20 BENZISOXAZOLES Y FENONAS COMO ALFA-2-ANTAGONISTAS , UN PROCESO PARA SU PREPARACIoN , COMPOSICIONES FARMACÉUTICAS Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO. AR021924A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98204358 1998-12-21

Publications (1)

Publication Number Publication Date
AR021924A1 true AR021924A1 (es) 2002-09-04

Family

ID=8234508

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106577A AR021924A1 (es) 1998-12-21 1999-12-20 BENZISOXAZOLES Y FENONAS COMO ALFA-2-ANTAGONISTAS , UN PROCESO PARA SU PREPARACIoN , COMPOSICIONES FARMACÉUTICAS Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO.

Country Status (30)

Country Link
US (1) US6576640B1 (es)
EP (1) EP1140934B1 (es)
JP (1) JP4717216B2 (es)
KR (2) KR100657540B1 (es)
CN (1) CN1154646C (es)
AR (1) AR021924A1 (es)
AT (1) ATE251622T1 (es)
AU (1) AU765751B2 (es)
BG (1) BG65162B1 (es)
BR (1) BR9916427A (es)
CA (1) CA2355716C (es)
CZ (1) CZ294532B6 (es)
DE (1) DE69911995T2 (es)
EA (1) EA003606B1 (es)
EE (1) EE200100329A (es)
ES (1) ES2209553T3 (es)
HK (1) HK1045686B (es)
HR (1) HRP20010444A2 (es)
HU (1) HUP0104812A3 (es)
ID (1) ID28967A (es)
IL (2) IL143830A0 (es)
NO (1) NO317892B1 (es)
NZ (1) NZ511411A (es)
PL (1) PL196958B1 (es)
SK (1) SK285560B6 (es)
TR (1) TR200101813T2 (es)
TW (1) TWI229673B (es)
UA (1) UA71938C2 (es)
WO (1) WO2000037466A1 (es)
ZA (1) ZA200105067B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2451606A1 (en) 2001-07-05 2003-01-16 Pharmacia & Upjohn Company (hetero) aryl substituted benzofurans as 5-ht ligands
CA2480266C (en) * 2002-04-03 2011-07-12 Orion Corporation Use of an alpha2-adrenoreceptor antagonist for cns-related diseases
CA2562406C (en) 2004-04-12 2013-03-19 Taisho Pharmaceutical Co., Ltd. Cyclic amine compound
MX2008000811A (es) * 2005-07-28 2008-03-18 Squibb Bristol Myers Co Tetrahidro-1h-pitido[4,3-b]indoles substituidos como agonistas y antagonistas del receptor de serotonina.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3382250A (en) * 1966-12-07 1968-05-07 Abbott Lab Aroylalkyl derivatives of 1, 2, 3, 4-tetrahydro-5h-pyrido[4, 3b]indoles
US3419568A (en) * 1966-12-07 1968-12-31 Abbott Lab Derivatives of 1,2,3,4-tetrahydro-5h-pyrido[4,3b]indoles
US3718657A (en) * 1970-12-03 1973-02-27 Abbott Lab Certain-2-substituted-1,2,3,4-tetrahydro-beta or gamma carbolines
JPS4729395U (es) * 1971-04-26 1972-12-04
US4001263A (en) * 1974-04-01 1977-01-04 Pfizer Inc. 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
AR207799A1 (es) * 1974-04-01 1976-10-29 Pfizer Procedimiento para preparar azaciclo(3,4-a)-n-fenilindoles-2-substituidos
US4224329A (en) * 1979-01-23 1980-09-23 Pfizer Inc. 2-Substituted-trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indoles
FR2570701B1 (fr) 1984-09-27 1987-05-22 Synthelabo Derives de furo(3,2-c)pyridines, leur preparation et leur application en therapeutique
DE3522959A1 (de) * 1985-06-27 1987-01-08 Merck Patent Gmbh Indolderivate
US4985422A (en) * 1988-04-27 1991-01-15 Glaxo Group Limited Lactam derivatives
WO1994008040A1 (en) * 1992-09-25 1994-04-14 Synaptic Pharmaceutical Corporation Dna encoding human alpha 1 adrenergic receptors and uses thereof
US5508306A (en) * 1992-11-13 1996-04-16 Synaptic Pharmaceutical Corporation Aromatic amine derivatives
US5403847A (en) 1992-11-13 1995-04-04 Synaptic Pharmaceutical Corporation Use of α1C specific compounds to treat benign prostatic hyperlasia
UA52681C2 (uk) 1997-04-08 2003-01-15 Янссен Фармацевтика Н.В. Похідні 1,2,3,4-тетрагідро-бензофуро[3,2,-c]піридину, спосіб їх одержання та фармацевтична композиція на їх основі

Also Published As

Publication number Publication date
PL196958B1 (pl) 2008-02-29
IL143830A0 (en) 2002-04-21
EA003606B1 (ru) 2003-06-26
CA2355716A1 (en) 2000-06-29
KR100657540B1 (ko) 2006-12-14
CN1154646C (zh) 2004-06-23
KR20060093139A (ko) 2006-08-23
NZ511411A (en) 2002-12-20
US6576640B1 (en) 2003-06-10
IL143830A (en) 2007-07-24
KR20010075650A (ko) 2001-08-09
ID28967A (id) 2001-07-19
PL348421A1 (en) 2002-05-20
HUP0104812A3 (en) 2003-12-29
UA71938C2 (en) 2005-01-17
NO20012783D0 (no) 2001-06-06
WO2000037466A1 (en) 2000-06-29
JP4717216B2 (ja) 2011-07-06
CA2355716C (en) 2010-05-18
NO20012783L (no) 2001-06-06
NO317892B1 (no) 2004-12-27
ES2209553T3 (es) 2004-06-16
BR9916427A (pt) 2001-09-04
AU765751B2 (en) 2003-09-25
BG65162B1 (bg) 2007-04-30
HUP0104812A2 (hu) 2002-04-29
SK8582001A3 (en) 2001-12-03
DE69911995T2 (de) 2004-09-02
EA200100709A1 (ru) 2001-12-24
ATE251622T1 (de) 2003-10-15
AU2432700A (en) 2000-07-12
DE69911995D1 (de) 2003-11-13
EP1140934B1 (en) 2003-10-08
EP1140934A1 (en) 2001-10-10
CZ294532B6 (cs) 2005-01-12
TR200101813T2 (tr) 2001-12-21
HRP20010444A2 (en) 2002-06-30
CZ20012120A3 (cs) 2001-10-17
BG105521A (en) 2001-12-29
SK285560B6 (sk) 2007-03-01
CN1331692A (zh) 2002-01-16
HK1045686A1 (en) 2002-12-06
EE200100329A (et) 2002-08-15
TWI229673B (en) 2005-03-21
HK1045686B (zh) 2005-04-01
ZA200105067B (en) 2002-06-20
JP2002533341A (ja) 2002-10-08

Similar Documents

Publication Publication Date Title
CO6270311A2 (es) Derivados bis-(sulfonilamino) en terapia 066
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
CO6270307A2 (es) Derivados bis-(sulfonilamino) en terapia
UY28671A1 (es) Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
UY28990A1 (es) Nuevos derivados de benceno 1, 3-amino carbonilo como inhibidores de b-raf, composiciones farmacéuticas que los contienen, procesos de preparación y uso.
CR7069A (es) Derivados de pirazol para el tratamiento de vih
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
UY27870A1 (es) Nuevos derivados de quinuclidina-amida
UY26872A1 (es) Derivados de la 4- fenil piridina
GT200400116A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
UY30327A1 (es) Nuevos compuestos ii
CR8649A (es) Derivados de formamidina para el tratamiento de enfermedades
AR006119A1 (es) Compuestos de quinoxalinadionas uso de los mismos para la fabricacion de un medicamento, compuestos de quinoxalinas para producirlos y procedimiento parala preparacion de los mismos
NO331174B1 (no) Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som neurokininantagonister
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
PA8589601A1 (es) Derivados de indazol como antagonistas del crf
BRPI0516748B8 (pt) pirimidinas 5-substituídas inibidoras de hiv e composição farmacêutica que as compreende
SV2004001548A (es) Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
ECSP066866A (es) Formas de dosificación y composiciones farmacéuticasreferencia a las solicitudes relacionadas
UY27850A1 (es) Nuevos carbamatos de quinuclidina y composiciones farmacéuticas que los contienen
UY26729A1 (es) Alquilaminas heterocíclicas como antagonistas de los receptores muscarínicos
SV2006002317A (es) Formulaciones de benzoxazoles substituidos ref. wyth0097-503 (am101641) (178701)

Legal Events

Date Code Title Description
FG Grant, registration